Short-term Increase in Risk of Overweight and Concomitant Systolic Blood Pressure Elevation in Treatment-Naive Persons Starting INSTI-Based Antiretroviral Therapy
Short-term Increase in Risk of Overweight and Concomitant Systolic Blood Pressure Elevation in Treatment-Naive Persons Starting INSTI-Based Antiretroviral Therapy
复制标题
DOI：
10.1093/ofid/ofz491
复制
发表时间：
2019-12-01
影响因子：
4.2
通讯作者：
Masia, Mar
中科院分区：
文献类型：
--
作者：
Galdamez, Ronald;Garcia, Jose A.;Masia, Mar
目标。整合酶链转移抑制剂（INSTI）与体重增加有关，但其对短期超重和肥胖发生率、血压（BP）和代谢指标的影响尚未在未接受治疗的HIV感染者（PWH）中得到描述。回顾性回顾了2007年1月至2019年7月期间在西班牙埃尔切大学医院艾滋病毒诊所开始抗逆转录病毒治疗（ART）的未接受治疗者的医疗记录。标准程序包括测量体重、血压和代谢评估。分析开始抗逆转录病毒治疗后基线、48周、72周和96周的数据。我们使用Cox混合效应模型来预测身体质量指数（BMI）随时间的变化，使用广义加性混合模型来放宽线性假设，并在多变量调整中产生95%的置信区间。219名参与者（中位年龄44.0岁；四分位数间距[IQR]， 37.0-53.5； 46名女性）。基线体重平均值（标准差）为70.4 (13.7)kg，两组间无差异；66%的人有BMI
Objective. Integrase strand transfer inhibitors (INSTI) have been associated with weight gain, but their effect on short-term overweight and obesity incidence, blood pressure (BP), and metabolic markers has not been described in treatment-naive people with HIV(PWH).Method. Medical records of treatment-naive persons starting antiretroviral therapy (ART) at the HIV Clinic of University Hospital of Elche, Spain, between January 2007 and July 2019 were reviewed retrospectively. Standard procedures included measurements of weight, BP, and metabolic assessment. Data at baseline, 48, 72, and 96 weeks post ART initiation were analyzed. We used Cox mixed-effects model to generate predictions of body mass index (BMI) over time and generalized additive mixed models to relax the linearity assumptions and generate 95% confidence intervals in the multivariable adjustment.Results. Among 219 (median age, 44.0 years; interquartile range [IQR], 37.0-53.5; 46 females) participants. Baseline weight mean (standard deviation) was 70.4 (13.7) kg without difference between regimens; 66% had a BMI